IP Library Granted Patent US 12,410,454
Granted Patent B2
US 12,410,454 · App. 17/323,769 · Granted Sep 9, 2025

Production of human milk oligosaccharides in microbial hosts with engineered import / export

Inventors: Stefan Jennewein (Bad Honnef, DE); Dirk Wartenberg (Bonn, DE)
Assignee: Chr. Hansen A/S
C12P19/18C12N9/1051C12N15/70C12Y204/01146
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,454
App. No.
17/323,769
Granted
Sep 9, 2025
Kind
B2
Abstract

The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.

Claims (31)

1. A method for production of an oligosaccharide by a genetically modified microbial host cell, wherein the oligosaccharide is a lacto-N-tetraose comprising a lacto-N-triose II (LNT-II; GlcNAc(b1-3)Gal(b1-4)Gluc) as a core trisaccharide, the method comprising:

providing a genetically modified microbial host cell that comprises:

at least one recombinant glycosyltransferase selected from the group consisting of a β-1,3-N-acetylglucosaminyltransferase and a β-1,3-galactosyltransferase;

increased expression or activity of at least one homologous or heterologous sugar export protein capable of exporting the oligosaccharide; and

decreased expression or inactivation of at least one export protein that exports LNT-II from the host cell;

cultivating the host cell in a medium under conditions permissive for the production of the oligosaccharide, whereby the oligosaccharide is exported into the medium at an increased level compared to an unmodified host cell, and

obtaining the oligosaccharide from the medium.

2. The method of claim 1 , wherein the host cell further comprises:

overexpression of at least one homologous or heterologous nucleic acid sequence coding for the sugar export protein capable of exporting the oligosaccharide into the culture medium; and/or

deletion, disruption, diminishment or inactivation of at least one endogenous nucleic acid sequence coding for an export protein that exports precursors of the oligosaccharide outside the host cell; and/or

overexpression of at least one homologous or heterologous sequence coding for a protein mediating import of a precursor of the oligosaccharide into said host cell, wherein the precursor is larger than a disaccharide.

3. The method of claim 2 , wherein said sugar export protein capable of exporting the oligosaccharide belongs to the class of secondary active transporters.

4. The method of claim 2 , wherein the nucleic acid sequence coding for the homologous or heterologous sugar export protein capable of exporting the oligosaccharide is of bacterial, archeal, plant, yeast or animal origin.

5. The method of claim 2 , wherein said at least one nucleic acid sequence coding for the sugar export protein that exports precursors of the oligosaccharide outside the host cell is a gene selected from the group consisting of yebQ from Escherichia coli , yjhB from Escherichia coli , proP from Mannheimia succiniciproducens , and setA from Cedecea neteri.

6. The method of claim 1 , wherein said β-1,3-N-acetylglucosaminyltransferase belongs to the class of lgtA of Neisseria meningitides or PmnagT of Pasteurella multocida.

7. The method of claim 1 , wherein the β-1,3-galactosyltransferase is encoded by a WbdO gene.

8. The method of claim 1 , wherein-ii the genetically modified microbial host cell further comprises an endogenous β-galactosidase gene and glucosamine-6-phosphate deaminase gene that are inactivated or deleted, and wherein said genetically modified microbial host cell further comprises a nucleic acid sequence coding for a functional lactose permease protein.

9. The method of claim 1 , wherein the genetically modified microbial host cell further comprises an increased UDP-N-acetylglucosamine and a UDP-galactose, or GDP-fucose, or CMP-N-acetylneuraminic acid production, as compared to a genetically unmodified host cell, wherein optionally said increased UDP-N-acetylglucosamine and UDP-galactose production capability is by an overexpression of one or more genes encoding a protein selected from the group consisting of L-glutamine:D-fructose-6-phosphate aminotransferase, N-acetyl glucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyl transferase, phosphoglucosamine mutase, UDP-galactose-4-epimerase, phosphoglucomutase, and glucose-1-phosphate uridylyltransferase.

10. The method of claim 8 , wherein said genetically modified microbial host cell is cultivated in the presence of glucose, sucrose, glycerol or a combination thereof.

11. The method of claim 10 , wherein the microbial host cell is cultured in the absence of N-acetylglucosamine and galactose.

12. A genetically modified microbial host cell for the production of lacto-N-tetraose comprising a lacto-N-triose II (LNT-II; GlcNAc(β1-3)Gal(β1-4)Gluc) as a core trisaccharide, wherein the host cell comprises

at least one recombinant glycosyltransferase, selected from the group consisting of a β-1,3-N-acetylglucosaminyltransferase and a β-1,3-galactosyltransferase;

at least one homologous or heterologous nucleic acid sequence coding for a sugar export protein capable exporting of the acto-N-tetraose into a culture medium the host cell is cultivated in wherein said sugar export protein capable of exporting the lacto-N-tetraose belongs to the class of secondary active transporters, and wherein said homologous or heterologous nucleic acid sequence coding for the sugar export protein capable of exporting the lacto-N-tetraose is overexpressed or under control of a promoter sequence enabling the overexpression of said nucleic acid sequence; and

inactivated expression or activity of at least one endogenous sugar export protein that exports LNT-II from the host cell.

13. The microbial host cell of claim 12 , further comprising an overexpression of at least one homologous or heterologous nucleic acid sequence coding for a protein mediating the import of a precursor of the acto-N-tetraose into said host cell through genetic modification of the microbial host cell, wherein the precursor is larger than a disaccharide.

14. The microbial host cell of claim 12 , wherein said nucleic acid sequence coding for the sugar export protein capable of exporting the acto-N-tetraose is of bacterial, archeal, plant, yeast or animal origin.

15. The microbial host cell of claim 12 , wherein said at least one nucleic acid sequence coding for the export protein that exports LNT-II from the host cell is a gene selected from the group consisting of yebQ from Escherichia coli , yjhB from Escherichia coli , proP from Mannheimia succiniciproducens , and setA from Cedecea neteri.

16. The microbial host cell of claim 14 , wherein the sugar export protein capable of exporting the lacto-N-tetraose is selected from the group consisting of YebQ from Escherichia coli BL21(DE3), SpoVB of Bacillus amyloliquefaciens , YabM of Erwinia pyrilfolia , Bcr of E. coli MG1655, YdeA of E. coli MG1655, ProP2 of Haemophilus parainfluenzae , SetA of Pectobacterium carotovorum , FucP of E. coli MG1655, MdeA of Staphylococcus aureus Bmb9393, ImrA of Lactococcus lactis , SetA of Pseudomonas sp. MT-1 and SetA of Beauveria bassiana Dl-5.

17. The method of claim 1 , wherein the sugar export protein capable of exporting the lacto-N-tetraose is selected from the group consisting of YebQ from Escherichia coli BL21(DE3), SpoVB of Bacillus amyloliquefaciens , YabM of Erwinia pyrilfolia , Bcr of E. coli MG1655, YdeA of E. coli MG1655, ProP2 of Haemophilus parainfluenzae , SetA of Pectobacterium carotovorum , FucP of E. coli MG1655, MdeA of Staphylococcus aureus Bmb9393, ImrA of Lactococcus lactis , SetA of Pseudomonas sp. MT-1 and SetA of Beauveria bassiana D1-5.

18. The method of claim 1 , wherein the microbial host cell is an Escherichia coli cell, a Corynebacterium glutamicum cell or a Saccharomyces sp. cell.

19. The microbial host cell of claim 12 , wherein the microbial host cell is an Escherichia coli cell, a Corynebacterium glutamicum cell or a Saccharomyces sp. cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: CHR. HANSEN HMO GMBH
To: CHR. HANSEN A/S
Reel/Frame 070396/0299 →
CHANGE OF NAME Recorded Apr 6, 2022
From: JENNEWEIN BIOTECHNOLOGIE GMBH
To: CHR. HANSEN HMO GMBH
Reel/Frame 059617/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2021
From: JENNEWEIN, STEFAN; WARTENBERG, DIRK
To: JENNEWEIN BIOTECHNOLOGIE GMBH
Reel/Frame 056366/0707 →
Priority Claims (1)
EP 15184968 · Sep 12, 2015 · regional
Continuity (2)
Continuation 15758653
Related Publication 20210277436A1 · Sep 9, 2021
References Cited (37)
US 8652808B2 · Jennewein · 2014 [cited by examiner]
US 9512433B2 · Jennewein et al. · 2016 [cited by applicant]
US 11046985B2 · Jennewein · 2021 [cited by examiner]
US 20110236934A1 · Samain et al. · 2011 [cited by applicant]
US 20120135467A1 · Jennewein et al. · 2012 [cited by applicant]
US 20140120611A1 · Jennewein et al. · 2014 [cited by applicant]
CN 103060252 · 2013 [cited by examiner]
EP 2722394A1 · 2014 [cited by applicant]
JP 2003504072A · 2003 [cited by applicant]
JP 2007525186A · 2007 [cited by applicant]
JP 2012529274A · 2012 [cited by applicant]
RU 2473695C2 · 2013 [cited by applicant]
WO 2007101862A1 · 2007 [cited by applicant]
WO WO2010142305A1 · 2010 [cited by examiner]
WO 2014122328A1 · 2014 [cited by applicant]
WO 2015032413A1 · 2015 [cited by applicant]
WO 2015106943A1 · 2015 [cited by applicant]
WO 2015117812A1 · 2015 [cited by applicant]
WO 2015150328A1 · 2015 [cited by applicant]
Koita, Dissertation, University of Illinois at Urbana Champaign, 2012, pp. 1-121 (Year: 2012). [cited by examiner]
Baumgartner, et al. ChemBioChem 2014, 15, pp. 1896-1900 (Year: 2014). [cited by examiner]
Pao, et al. Microbiology and Molecular Biology Reviews (1998) pp. 1-34 (Year: 1998). [cited by examiner]
Han, et al. Biotechnology Advances 30 (2012) pp. 1268-1278 (Year: 2012). [cited by examiner]
Vincent, et al. JBC, vol. 280, Issue 20, 2005, pp. 19649-19655 (Year: 2005). [cited by examiner]
Baumgartner, et al Enzyme and Microbial Technology 75-76 (2015) pp. 37-43 (Year: 2015). [cited by examiner]
Smilovitz et al.; Breast milk oligosaccharides: structure-function relationships in the neonate; Annu. Rev. Nutr. (2014) 34:143-169. [cited by applicant]
PCT International Search Report for PCT/EP2016/071420, mailed Oct. 28, 2016. [cited by applicant]
Weichert, et al., “Bioengineered 2′-fucosyllactose and 3-fucosyllactose inhibit the adhesion of [cited by applicant]
Jennewein: “Abschlussbericht zum Forderprojekt Entwicklung eines innovativen Produktionsverfahrens fur Fucosyllctosen Mit dem,” Jennewein Biotechnologie GmbH, Project Report, 2012, pp. 1-31. [cited by applicant]
Khushnuma Koita, “Optimizing Pentose Sugar Utilization in [cited by applicant]
Koita, et al., “Identification and Analysis of the Putative Pentose Sugar Efflux Transporters in [cited by applicant]
Baumgärtner, et al., “Construction of [cited by applicant]
Petschacher, et al., “Biotechnological production of fucosylated human milk oligosaccharides: Prokaryotic fucosyltransferases and their use in biocatalytic cascades or whole cell conversion systems,” Journal of Biotechn… [cited by applicant]
Baumgärtner, et al., “Synthesis of fucosylated lacto-N-tetraose using whole-cell biotransformation,” Bioorganic & Medicinal Chemistry, (2015), vol. 23: 6799-6806. [cited by applicant]
Saumonneau et al.,“Design of an alpha-L-transfucosidase for the synthesis of fucosylated HMOs,” Glycobiology, (2016), vol. 26, No. 3: 261-269. [cited by applicant]
Bernard Priem, et al., “A new fermentation process allows large-scale production of human milk oligosaccharides by metabolically engineered bacteria,” Glycobiology, (2002), vol. 12, No. 4: 235-240. [cited by applicant]
Florian Baumgartner, “Synthesis of the Human Milk Oligosaccaride Lacto-N-Tetraose in Metabolically Engineered, Plasmid-Free [cited by applicant]